Inozyme Pharma News

Inozyme Pharma to Present Recently Announced Data From Phase 1/2 Trials of INZ-701 in Adults With ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

GlobeNewswireMay 23 20:30

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

GlobeNewswireMay 8 20:30

Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham

Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham

Dow JonesMay 8 18:27

Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects

TipRanksMay 8 18:18

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)

TipRanksMay 8 17:40

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)

TipRanksMay 8 17:32

Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities

TipRanksMay 8 17:31

Inozyme Pharma GAAP EPS of -$0.38 Beats by $0.02

Seeking AlphaMay 8 15:54

Inozyme Pharma Q1 EPS $(0.38) Misses $(0.36) Estimate

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 5 percent increase over losses of $(0.40)

BenzingaMay 7 20:49

Inozyme Pharma | 10-Q: Quarterly report

Futu NewsMay 7 20:34 · Announcements

Inozyme Pharma: Runway To Fund Operations Into 4Q 2025 >INZY

Inozyme Pharma: Runway To Fund Operations Into 4Q 2025 >INZY

Dow JonesMay 7 20:32

Press Release: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiv

Dow JonesMay 7 20:30

Inozyme Pharma 1Q Loss/Shr 38c >INZY

Inozyme Pharma 1Q Loss/Shr 38c >INZY

Dow JonesMay 7 20:30

RMBS, SANM and WGS Are Among After Hour Movers

Seeking AlphaApr 30 05:00

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings

BenzingaApr 30 04:31

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.

BenzingaApr 10 01:12

Inozyme Pharma Is Maintained at Buy by B of A Securities

Inozyme Pharma Is Maintained at Buy by B of A Securities

Dow JonesApr 10 00:47

B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma with a Buy and lowers the price target from $16 to $14.

Analyst UpgradesApr 10 00:38

Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.

Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.

Zhitong FinanceApr 9 20:02

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Needham analyst Joseph Stringer reiterates Inozyme Pharma with a Buy and maintains $23 price target.

Analyst UpgradesApr 9 19:56